Abstract
Regulatory T lymphocytes (Tregs) are specialized for immune suppression and are important regulators of the immune response in various settings. Tregs actively suppress enteroantigen-reactive cells and contribute to the maintenance of intestinal immune homeostasis. Distinct Treg subsets coexist in the intestinal mucosa and mesenteric lymph nodes. Disturbances in Treg number and function are associated with immune-mediated disorders. Therefore, Tregs are potential targets for immunotherapies. The gut mucosal immune system is the largest lymphoid organ in the body. This site has continuous antigenic challenges from food antigens, antigens of the abundant normal bacterial flora, and pathogens. Despite this constant antigenic stimulation, controlled inflammatory responses and suppression of inflammation appear to be the rule. The gut immune system differentiates the antigenic signals from the high background noise of food and bacterial antigens. This tight regulation required to maintain homeostasis is achieved through multiple non-immune and immune factors. Oral tolerance is a mechanism in which the gastrointestinal immune system inhibits or promotes its reaction toward an orally administered antigen. Mucosal tolerance is attractive as an approach to the treatment of autoimmune and inflammatory diseases; the benefits of using an oral tolerance approach are: lack of toxicity, ease of administration over time, and antigen-specific mechanisms of action. Multiple mechanisms of tolerance are induced by oral antigen administration. Recent data suggest that oral antigen administration of antigens may promote activation of different types of regulatory T lymphocytes, enabling treatment of immune mediated disorders. This review summarizes the recent data on induction of regulatory T-cells by oral antigen administration as a possible mechanism of oral tolerance.
Keywords: Oral tolerance, regulatory T-cells
Current Pharmaceutical Design
Title: The Gut Mucosa as a Site for Induction of Regulatory T-Cells
Volume: 15 Issue: 11
Author(s): Meir Mizrahi and Yaron Ilan
Affiliation:
Keywords: Oral tolerance, regulatory T-cells
Abstract: Regulatory T lymphocytes (Tregs) are specialized for immune suppression and are important regulators of the immune response in various settings. Tregs actively suppress enteroantigen-reactive cells and contribute to the maintenance of intestinal immune homeostasis. Distinct Treg subsets coexist in the intestinal mucosa and mesenteric lymph nodes. Disturbances in Treg number and function are associated with immune-mediated disorders. Therefore, Tregs are potential targets for immunotherapies. The gut mucosal immune system is the largest lymphoid organ in the body. This site has continuous antigenic challenges from food antigens, antigens of the abundant normal bacterial flora, and pathogens. Despite this constant antigenic stimulation, controlled inflammatory responses and suppression of inflammation appear to be the rule. The gut immune system differentiates the antigenic signals from the high background noise of food and bacterial antigens. This tight regulation required to maintain homeostasis is achieved through multiple non-immune and immune factors. Oral tolerance is a mechanism in which the gastrointestinal immune system inhibits or promotes its reaction toward an orally administered antigen. Mucosal tolerance is attractive as an approach to the treatment of autoimmune and inflammatory diseases; the benefits of using an oral tolerance approach are: lack of toxicity, ease of administration over time, and antigen-specific mechanisms of action. Multiple mechanisms of tolerance are induced by oral antigen administration. Recent data suggest that oral antigen administration of antigens may promote activation of different types of regulatory T lymphocytes, enabling treatment of immune mediated disorders. This review summarizes the recent data on induction of regulatory T-cells by oral antigen administration as a possible mechanism of oral tolerance.
Export Options
About this article
Cite this article as:
Mizrahi Meir and Ilan Yaron, The Gut Mucosa as a Site for Induction of Regulatory T-Cells, Current Pharmaceutical Design 2009; 15 (11) . https://dx.doi.org/10.2174/138161209787846784
DOI https://dx.doi.org/10.2174/138161209787846784 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
<i>Propionibacterium acnes</i> in the Pathogenesis and Immunotherapy of Acne Vulgaris
Current Drug Metabolism Endophthalmitis
Anti-Infective Agents in Medicinal Chemistry Peculiarities of the Clinical Course of Oxidative Protein and Lipid Modification in Children with Acute Rheumatic Fever
Endocrine, Metabolic & Immune Disorders - Drug Targets Biofilms: An Extra Hurdle for Effective Antimicrobial Therapy
Current Pharmaceutical Design Cardiac Tumors: Clinical Perspective and Therapeutic Considerations
Current Drug Targets Nanomedical Strategies for Targeting Skin Microbiomes
Current Drug Metabolism Probiotics: From Functional Foods to Pharmaceutical Products
Current Pharmaceutical Biotechnology Value of Real Time Three Dimensional Transesophageal Echocardiography in General Cardiology Practice
Recent Patents on Medical Imaging Anti-MRSA Cephems: An Update
Current Medicinal Chemistry - Anti-Infective Agents Quorum Sensing Inhibitors from the Sea: Lessons from Marine Symbiotic Relationships
Current Organic Chemistry Effect of Silver Nanoparticles (AgNPs) on <i>Candida albicans, Candida dubliniensis</i> and <i>Candida guilliermondii</i>
Current Drug Therapy High Incidence of Infections in HIV-positive Patients Treated for Lymphoproliferative Disorders
Current HIV Research DNA Microarrays - An Armory for Combating Infectious Diseases in the New Century
Infectious Disorders - Drug Targets Rheumatoid Nodulosis in a Patient with Lupus Erythematosus: Case Report and Review
Current Rheumatology Reviews Heart Failure in South America
Current Cardiology Reviews Exploiting Quorum Sensing Inhibition for the Control of Pseudomonas aeruginosa and Acinetobacter baumannii Biofilms
Current Topics in Medicinal Chemistry Pulmonary Disease in Beta-Thalassemia
Current Respiratory Medicine Reviews Clinical Presentations and Diagnosis of Brucellosis
Recent Patents on Anti-Infective Drug Discovery Clinical Pharmacology and Lesion Penetrating Properties of Second- and Third-Line Antituberculous Agents Used in the Management of Multidrug-Resistant (MDR) and Extensively-Drug Resistant (XDR) Tuberculosis
Current Clinical Pharmacology Neuromuscular Disorders in Left Ventricular Hypertrabeculation/Noncompaction
Current Pharmaceutical Design